Gilead (NASDAQ: GILD) CFO sells 3,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Gilead Sciences’ Chief Financial Officer Andrew D. Dickinson reported a small, pre-planned stock sale. On January 15, 2026, he sold 3,000 shares of Gilead common stock at a price of $124.31 per share. After this transaction, he continued to beneficially own 150,503 shares of the company’s common stock in direct ownership.

The sale was executed under a Rule 10b5-1 trading plan that was adopted on August 29, 2024, meaning the trade was scheduled in advance under a preset plan rather than being decided at the time of sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dickinson Andrew D

(Last) (First) (Middle)

GILEAD SCIENCES, INC.

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/15/2026		S(1)		3,000	D	$124.31	150,503	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Remarks:

	/s/ Amy Kim by Power of Attorney for Andrew D. Dickinson	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Gilead Sciences (GILD) report for its CFO?

Gilead Sciences’ Chief Financial Officer Andrew D. Dickinson reported the sale of 3,000 shares of Gilead common stock on January 15, 2026.

At what price did the Gilead (GILD) CFO sell his shares?

The 3,000 Gilead common shares were sold at a price of $124.31 per share.

How many Gilead (GILD) shares does the CFO own after the reported sale?

Following the transaction, Andrew D. Dickinson beneficially owned 150,503 shares of Gilead common stock in direct ownership.

Was the Gilead (GILD) CFO’s share sale under a Rule 10b5-1 plan?

Yes. The transaction was made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

What type of filing reported the Gilead (GILD) CFO stock sale?

The transaction was disclosed in a Form 4, which reports changes in the beneficial ownership of a company’s equity securities by insiders.

Is the Gilead (GILD) CFO an officer, director, or large shareholder?

Andrew D. Dickinson is reported as an officer of Gilead Sciences with the title Chief Financial Officer, and is not listed as a 10% owner.